Biogen IDP

XET: IDP | ISIN: US09062X1037   12/11/2024
159,85 EUR (-1,81%)
(-1,81%)   12/11/2024
Grafiek Biogen Inc. Grafiek Biogen Inc.

Biogen Inc. in het nieuws

14 november 2024 · Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease · Persbericht

31 oktober 2024 · Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference · Persbericht

29 oktober 2024 · Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases · Persbericht

29 oktober 2024 · Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer · Persbericht

28 oktober 2024 · Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025 · Persbericht

27 oktober 2024 · Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 · Persbericht

24 oktober 2024 · Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference · Persbericht

22 oktober 2024 · Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024 · Persbericht

9 oktober 2024 · Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients · Persbericht

8 oktober 2024 · New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA · Persbericht

Profiel Biogen Inc.

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Website: www.biogen.com

Hoofdzetel: Cambridge, Massachusetts vlag Verenigde Staten

CEO: George Scangos

Werknemers: 13.414

Mijn selecties